בנדמוסטין מדאק 25 מג
tzamal bio-pharma ltd - bendamustine hydrochloride - אבקה להכנת תמיסה מרוכזת לעירוי - bendamustine hydrochloride 25 mg - bendamustine
הידרוקסיאוריאה מדאק 500 מג
tzamal bio-pharma ltd - hydroxycarbamide - קפסולות - hydroxycarbamide 500 mg - hydroxycarbamide
גליולן
tzamal bio-pharma ltd - 5-aminolevulinic acid as hydrochloride - אבקה להכנת תמיסה - 5-aminolevulinic acid as hydrochloride 1.5 g - aminolevulinic acid - aminolevulinic acid - gliolan® is indicated in adult patients for visualisation of malignant tissue during surgery for malignant glioma (who grade iii and iv).
גליולן
tzamal bio-pharma ltd - 5-aminolevulinic acid hydrochloride - אבקה להכנת תמיסה - 5-aminolevulinic acid hydrochloride 1.5 g - aminolevulinic acid
יורוקינאז מדאק 1,000,000 iu
tzamal bio-pharma ltd - urokinase 1000000 iu - powder for solution for injection - urokinase - peripheral arterial thrombosis ;acute and subacute deep vein thrombosis ; acute diagnostically confirmed pulmonary embolism, in particular when associated with unstable haemodynamic status ; thrombosed arteriovenous shunt.
מטוג'קט 10 מ"ג /מ"ל
tzamal bio-pharma ltd - methotrexate 10 mg/ml - solution for injection - methotrexate - psoriasis:because of the high risk attending its use, methotrexate is indicated only in the symptomatic control of severe recalcitrant, disabling psoriasis which is not adequately responsive to other forms of therapy, and only when the diagnosis has been established, as by biopsy and/or after dermatological consultation. rheumatoid arthritis: methotrexate can be used in the treatment of selected adults with severe rheumatoid arthritis, only when the diagnosis has been well estabished according to rheumatological standards, with inadequate response to other forms of antirheumatic therapy, including full dose nsaids and usually a trial of at least one or more disease-modifying antirheumatic drugs.
מטוג'קט 50 מ"ג / מ"ל
tzamal bio-pharma ltd - methotrexate 50 mg/ml - solution for injection - methotrexate - psoriasis:because of the high risk attending its use, methotrexate is indicated only in the symptomatic control of severe recalcitrant, disabling psoriasis which is not adequately responsive to other forms of therapy, and only when the diagnosis has been established, as by biopsy and/or after dermatological consultation. rheumatoid arthritis: methotrexate can be used in the treatment of selected adults with severe rheumatoid arthritis, only when the diagnosis has been well estabished according to rheumatological standards, with inadequate response to other forms of antirheumatic therapy, including full dose nsaids and usually a trial of at least one or more disease-modifying antirheumatic drugs.juvenile idiopathic arthritis:treatment of polyarthritic forms of severe, active juvenile idiopathic arthritis when the response to non-steroidal anti-inflammatory drugs (nsaids) has been inadequate